Stockscreener 앱 받기
8.96
1.43%
-0.13
시간 외 거래:
9.14
0.18
+2.01%
전일 마감가:
$9.09
열려 있는:
$9.08
하루 거래량:
1.54M
Relative Volume:
0.57
시가총액:
$1.35B
수익:
-
순이익/손실:
$-738.82M
주가수익비율:
-1.2873
EPS:
-6.9602
순현금흐름:
$-610.15M
1주 성능:
-9.59%
1개월 성능:
-21.33%
6개월 성능:
-37.43%
1년 성능:
-68.83%
1일 변동 폭
$8.76
$9.38
1주일 범위
$8.76
$10.37
52주 변동 폭
$7.48
$31.18
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
8.96 | 1.37B | 0 | -738.82M | -610.15M | -6.9602 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-06 | 개시 | Goldman | Buy |
| 2026-01-21 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-11-06 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-09-17 | 개시 | Citigroup | Buy |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-05-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-09-16 | 개시 | Jefferies | Buy |
| 2024-09-04 | 개시 | Bernstein | Outperform |
| 2024-07-24 | 개시 | Morgan Stanley | Overweight |
| 2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2023-12-22 | 개시 | H.C. Wainwright | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-01-24 | 개시 | SVB Securities | Outperform |
| 2023-01-04 | 개시 | JP Morgan | Overweight |
| 2022-12-02 | 개시 | BTIG Research | Buy |
| 2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | 개시 | Piper Sandler | Overweight |
| 2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-08-03 | 재확인 | Canaccord Genuity | Buy |
| 2021-03-11 | 개시 | UBS | Buy |
| 2020-12-15 | 개시 | H.C. Wainwright | Buy |
| 2020-04-17 | 개시 | Cowen | Outperform |
| 2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2019-11-22 | 개시 | Wedbush | Outperform |
| 2019-06-25 | 재확인 | Canaccord Genuity | Buy |
| 2019-05-06 | 개시 | Goldman | Buy |
| 2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | 재확인 | Needham | Buy |
| 2018-07-03 | 재확인 | Needham | Buy |
| 2018-07-02 | 재확인 | Needham | Buy |
| 2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2018-02-22 | 재확인 | Canaccord Genuity | Buy |
| 2017-12-15 | 개시 | Canaccord Genuity | Buy |
| 2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust - Stock Titan
Biohaven shares edge higher after completing enrollment in obesity drug trial - MSN
Risk Off: What is the long term forecast for Biohaven Ltd stock2026 Market WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Biohaven Therapeutics discloses prodrugs of betahistine - BioWorld MedTech
Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa - marketscreener.com
Biohaven completes enrollment in obesity drug trial - Investing.com
Biohaven stock rises as obesity trial completes enrollment - Investing.com
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment - PR Newswire
Biohaven has completed enrollment for its obesity study—However, the market still hasn't factored in the potential risk of the trial not succeeding - Bitget
Precision Trading with Biohaven Ltd. (BHVN) Risk Zones - Stock Traders Daily
Pullback Watch: Is Biohaven Ltd on track to beat earnings2026 EndofMonth & High Win Rate Trade Alerts - baoquankhu1.vn
Valuation Update: What are analysts price targets for Biohaven LtdMarket Sentiment Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Biohaven Ltd. ($BHVN) CEO 2025 Pay Revealed - Quiver Quantitative
Integral Health Asset Management LLC Buys 350,000 Shares of Biohaven Ltd. $BHVN - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Biohaven (NYSE: BHVN) outlines R&D pipeline and 2026 shareholder votes - Stock Titan
Capital Research Global Investors Raises Position in Biohaven Ltd. $BHVN - MarketBeat
Macro Review: Is Biohaven Ltd gaining market shareWeekly Trading Summary & Technical Entry and Exit Tips - baoquankhu1.vn
TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00 - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Dyne Therapeutics (DYN), Biohaven Ltd. (BHVN) and Teladoc (TDOC) - The Globe and Mail
Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment - simplywall.st
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why Biohaven (BHVN) Is Down 13.5% After Narrower Losses And A New Share Shelf Registration - simplywall.st
Raymond James Maintains Strong Buy on Biohaven Ltd. (BHVN) March 2026 - Meyka
Biohaven (BHVN) director trust purchase corrected to 28,400 shares - Stock Titan
Raymond James reiterates Strong Buy on Biohaven stock after competitor data - Investing.com Australia
Raymond James reiterates Strong Buy on Biohaven stock after competitor data By Investing.com - Investing.com South Africa
Biohaven Reports Q4 EPS Beat Expectations, Plans Stock Issuance - Intellectia AI
Biohaven (NYSE:BHVN) Shares Gap UpTime to Buy? - MarketBeat
Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets - Bez Kabli
What's Going On With Biohaven Stock On Monday? - Benzinga
Breakout Watch: Can Biohaven Ltd stock outperform in a bear marketJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Death Cross: Is Biohaven Ltd a stock for growth or value investors2025 Winners & Losers & Reliable Trade Execution Plans - baoquankhu1.vn
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven stock price target lowered to $10 by H.C. Wainwright - Investing.com South Africa
Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright - MarketBeat
BHVN Earnings History & Surprises | EPS & Revenue Results | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BHVN: HC Wainwright & Co. Lowers Price Target While Maintaining - GuruFocus
Assessing Biohaven (BHVN) Valuation After Recent Share Price Volatility - simplywall.st
Biohaven Reshapes Pipeline And Funding As Late Stage Trials Approach - Yahoo Finance
Biohaven (BHVN) VP and CAO awarded 50,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) CFO awarded 175,000 stock options in Form 4 filing - Stock Titan
Biohaven Ltd. (BHVN) SVP awarded 175,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) Chief Scientific Officer awarded 175,000 stock options - Stock Titan
Biohaven (BHVN) CEO Vlad Coric granted 550,000 stock options - Stock Titan
Key facts: Biohaven posts $738.8M loss; opakalim shows promise in study; analysts give 'buy' rating - TradingView
Biohaven (NYSE:BHVN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts By Investing.com - Investing.com Canada
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts - Investing.com Nigeria
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 77% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):